Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Relapse after HSCT 2021
At #IMS26, we had the pleasure of speaking with @RahulBanerjeeMD of @fredhutch, who discussed defining 'functional cure' and how this concept may influence treatment goals in #multiplemyeloma.
For his exclusive insights, click here:
🎥 👉
#Myeloma
Defining functional cure and evolving treatment goals in multiple myeloma
Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, discusses how he defines “functional cure” i...
ow.ly
How can we bridge the gap between innovation and community practice in acute lymphoblastic #leukemia treatment? 🩸
At #SOHO2026, @bshah of @MoffittNews discussed this, highlighting the need for better education and earlier integration of novel therapies into clinical trials:
👉
Hear updated data from the COMMANDS trial evaluating luspatercept versus ESAs in LR-MDS. 🚨
@Santin13Valeria of @UNI_FIRENZE, shared insights into these findings at #SOHO2026. Click here to watch:
🎥 ➡️
#TrialUpdate #CTSM #MDSsm #HemOnc
Updated OS and long-term data from the COMMANDS trial: luspatercept versus ESAs in LR-MDS
Valeria Santini, MD, University of Florence, Florence, Italy, comments on updated results from the COMMANDS trial (NCT...
ow.ly
Is a cancer-specific CHIP risk score required to improve cardio-oncology monitoring?
Find out from Jaiveer Singh of @YaleMed, who shared his insights at #ESCCongress:
👉 👈
#CardioOnc @escardio
Is a cancer-specific CHIP risk score required to improve cardio-oncology monitoring?
Jaiveer Singh, MS, Yale University School of Medicine, New Haven, CT, discusses the need for further research into ...
ow.ly
How can patient advocacy groups work with pharma to advance patient-centered immunotherapy trials in #multiplemyeloma?🩸
Doris Hansen of @MoffittNews answered this question in a recent interview. Click here to hear her insights:
🎥
#CTSM #Myeloma #MMsm
Designing immunotherapy trials in multiple myeloma: how advocacy groups can work with pharma
Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, discusses how patient advocacy groups and the pharmaceutical indus...
ow.ly
Relapse after HSCT 2021
At #IMS26, we had the pleasure of speaking with @RahulBanerjeeMD of @fredhutch, who discussed defining 'functional cure' and how this concept may influence treatment goals in #multiplemyeloma.
For his exclusive insights, click here:
🎥 👉
#Myeloma
Defining functional cure and evolving treatment goals in multiple myeloma
Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, discusses how he defines “functional cure” i...
ow.ly
How can we bridge the gap between innovation and community practice in acute lymphoblastic #leukemia treatment? 🩸
At #SOHO2026, @bshah of @MoffittNews discussed this, highlighting the need for better education and earlier integration of novel therapies into clinical trials:
👉
Hear updated data from the COMMANDS trial evaluating luspatercept versus ESAs in LR-MDS. 🚨
@Santin13Valeria of @UNI_FIRENZE, shared insights into these findings at #SOHO2026. Click here to watch:
🎥 ➡️
#TrialUpdate #CTSM #MDSsm #HemOnc
Updated OS and long-term data from the COMMANDS trial: luspatercept versus ESAs in LR-MDS
Valeria Santini, MD, University of Florence, Florence, Italy, comments on updated results from the COMMANDS trial (NCT...
ow.ly
Is a cancer-specific CHIP risk score required to improve cardio-oncology monitoring?
Find out from Jaiveer Singh of @YaleMed, who shared his insights at #ESCCongress:
👉 👈
#CardioOnc @escardio
Is a cancer-specific CHIP risk score required to improve cardio-oncology monitoring?
Jaiveer Singh, MS, Yale University School of Medicine, New Haven, CT, discusses the need for further research into ...
ow.ly
How can patient advocacy groups work with pharma to advance patient-centered immunotherapy trials in #multiplemyeloma?🩸
Doris Hansen of @MoffittNews answered this question in a recent interview. Click here to hear her insights:
🎥
#CTSM #Myeloma #MMsm
Designing immunotherapy trials in multiple myeloma: how advocacy groups can work with pharma
Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, discusses how patient advocacy groups and the pharmaceutical indus...
ow.ly
